Company intelligence / Profile preview

CVRx

Minneapolis, Minnesota, United Statescvrx.com ↗

Ownership: Public · CVRX
Employees: ~150
Development stage: Commercial

Overview

The Barostim system has demonstrated significant clinical benefit in heart failure patients, including improved exercise capacity (~60 yards farther in six-minute walk test), quality of life scores nearly three times higher than medication alone, and a high response rate with symptom improvement. FDA Premarket Approval was granted in 2019 for heart failure indication. As of year-end 2024, commercial adoption and revenue growth are strong.

Therapeutic areas: Cardiovascular
Modalities: DeviceNeuromodulation therapy (medical device-based)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Barostim Neo

Commercial

Indications: Heart failure, Resistant hypertension

Partnerships

None specifically disclosed; reimbursement partnerships with payors like Medicare/private insurers are operationally important.

Financials

Market cap: $75.1M
Total revenue: $15.7M
Enterprise value: $69.9M

Beyond the preview

Go deeper on CVRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVRx.

Explore the full profile